OMDA vs WST
Omada Health vs West Pharmaceutical Services — AI-powered side-by-side comparison
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | OMDA | WST |
|---|
| AI Score |
59
|
74
|
| Price |
$24.00
|
$351.74
|
| P/E Ratio |
353.61×
|
44.65×
|
| ROE |
-5.6%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.2%
|
36.8%
|
| Debt / Equity |
0.00×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
66.6
|
58.0
|
| Beta |
1.7204
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for OMDA versus WST.
WST leads by 15 points.
WST scores 74/100 (Buy) versus OMDA at 59/100 (Buy).
OMDA Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 35.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Bollinger bandwidth of 35.5% signals elevated volatility — Risk
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical